Circulating VE-cadherin in patients with controlled chronic lymphocytic leukemia

• Main Author: 10.14739/2310-1237.2014.2.28551
• Format: Article
• Language: English
• Published: Zaporozhye State Medical University 2014-08-01
• Series: Patologìâ
• Subjects: VE-cadherin; Chronic Lymphocytic Leukemia; Survival; Prognosis
• Online Access: http://pat.zsmu.edu.ua/article/view/28551/25530

Aim. To evaluate the prognostic value of circulating VE-cadherin for cumulative survival in asymptomatic coronary artery disease patients with full or partial remission of limphoproliferative diseases. Methods. One hundred twelve patients with full or partial remission of chronic lymphocytic leukemia were enrolled in the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-cadherin was used. Concentrations of VE-cadherin for cumulative survival cases due to advanced CHF were tested. Results. One hundred three cumulative clinical events occurred in 45 patients (40.2%) within the follow-up, with their distribution being as follows: 25 deaths, 73 cardiac arrhythmias, 12 cardiac ischemic events, 2 strokes, 30 chronic heart failures and 38 hospital admissions for cardiovascular reasons. Medians of circulating levels of VE-cadherin in free-events subject cohort and subjects cohort with cardiovascular events were 0,31 ng/ml (95% confidence interval [CI] = 0,19-0,43 ng/ml) and 1,49 ng/ml (95% CI = 1,07–1,91 ng/ml) (P<0.001). In multivariate logistic regression circulating VE-cadherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1,11; 95% CI = 1,01–1,14; P = 0.001) within 12 months of observation period. However, NT-pro-BNP and Е/Em remained statistically significant predictors for cumulative cardiovascular events (OR = 1,06; 95% CI 1,03–1,14; P < 0.001 and OR = 1,05; 95% CI = 1,01 – 1,09; P<0,001), whereas T2DM, hypertension, obesity, LVEF, and multi-vessel lesion did not. Conclusion. Among patients with documented limphoproliferative diseases and known asymptomatic coronary artery disease increased circulating VE-cadherin associates with increased cumulative cardiovascular events.